李健, 王敏, 田川. 特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响[J]. 实用临床医药杂志, 2018, (5): 39-41,44. DOI: 10.7619/jcmp.201805012
引用本文: 李健, 王敏, 田川. 特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响[J]. 实用临床医药杂志, 2018, (5): 39-41,44. DOI: 10.7619/jcmp.201805012
LI Jian, WANG Min, TIAN Chuan. Effects of terlipressin combined with alprostadil on hepatic and renal function in liver cirrhosis patients with refractory ascites[J]. Journal of Clinical Medicine in Practice, 2018, (5): 39-41,44. DOI: 10.7619/jcmp.201805012
Citation: LI Jian, WANG Min, TIAN Chuan. Effects of terlipressin combined with alprostadil on hepatic and renal function in liver cirrhosis patients with refractory ascites[J]. Journal of Clinical Medicine in Practice, 2018, (5): 39-41,44. DOI: 10.7619/jcmp.201805012

特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响

Effects of terlipressin combined with alprostadil on hepatic and renal function in liver cirrhosis patients with refractory ascites

  • 摘要: 目的 探讨特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响.方法 选择74例肝硬化难治性腹水患者,随机分为2组.对照组行前列地尔治疗,观察组在此基础上联用特利加压素,比较2组治疗前与治疗2周后肝肾功能指标变化情况与门静脉内径与脾静脉内径.结果 观察组治疗2周后尿氮素(BUN)、血肌酐(Scr)含量均显著低于对照组,24h尿量显著高于对照组(P<0.05);观察组患者治疗2周后白蛋白(ALB)水平显著高于对照组,总胆红素(TBIL)水平显著低于对照组(p<0.05);观察组治疗2周后门静脉内径与脾静脉内径均显著低于对照组(P<0.05).结论 特利加压素与前列地尔联合治疗肝硬化难治性腹水患者效果显著.

     

/

返回文章
返回